Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Prevention becomes predictive: How Abu Dhabi is learning to read health risks before symptoms appear

For a family welcoming a newborn, prevention can begin before there is any outward sign of illness. For an adult attending a routine check-up, it could mean understanding a developing health risk early enough to change its course. These are the possibilities behind Abu Dhabi’s move towards predictive health care. Advice on exercise, nutrition and regular screening remains essential. The next step…

Prevention becomes predictive: How Abu Dhabi is learning to read health risks before symptoms appear

Abu Dhabi is pioneering predictive healthcare, aiming to detect health risks before symptoms emerge. This shift emphasizes personalized prevention based on genetic profiles, medical history, and health metrics. The Abu Dhabi Future Health Summit focuses on translating genomics, data, and artificial intelligence into evidence-based care decisions.

These advancements can help identify inherited conditions, assess risk factors, and guide appropriate screening and treatment. Initiatives like the Newborn Genetic Screening Programme offer early detection of treatable genetic disorders through cord blood analysis. Meanwhile, the Population Health Intelligence platform aggregates clinical, lifestyle, and environmental data to identify emerging risks and guide targeted prevention efforts.

Ultimately, predictive healthcare seeks to empower patients and families with earlier insights into their health, leading to better outcomes and a higher quality of life.

Written by urgent.news from The National UAE's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at thenationalnews.com →

More in Health & Medicine

LigaChem Doses First Patient in Global Trial of Cancer-Targeting ADC

LigaChem Biosciences has begun global clinical development of its proprietary Claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC) candidate, LCB02A. The company announced on Oct.

  • LigaChem begins global Phase 1/2 trial for CLDN18.2-targeting ADC LCB02A on October 15
  • Study involves up to 191 patients with advanced solid tumors expressing CLDN18.2
  • ADC uses LigaChem's ConjuAll platform with exatecan cytotoxic payload

More from Friday 16 October →